Table 3.
Ocular baseline characteristics.
| Number of patients | MS group | Reference group | Group difference | ||
|---|---|---|---|---|---|
| All patients with MS | Patients without MS‐ON1 | Patients with MS‐ON | Healthy participants | p‐value* | |
| N = 333 | N = 235 | N = 98 | N = 64 | ||
| Retinal thickness (μm) | |||||
| pRNFL | 89.0 ± 15.30 | 91.7 ± 14.21 | 82.5 ± 15.85 | 100.2 ± 9.23 | <0.0001 |
| mGCIPL | 79.3 ± 14.22 | 82.2 ± 12.91 | 72.5 ± 14.94 | 91.9 ± 8.42 | <0.0001 |
| Visual acuity (ETDRS letters) | |||||
| High contrast | 56.1 ± 9.49 | 57.0 ± 8.25 | 53.8 ± 11.69 | 59.6 ± 5.42 | <0.0001 |
| Low contrast | 27.8 ± 11.65 | 29.8 ± 10.44 | 22.9 ± 12.95 | 34.3 ± 7.28 | <0.0001 |
Values are mean ± SD. N is the total number of subjects in the analysis population.
ETDRS, early treatment diabetic retinopathy study; mGCIPL, combined macular ganglion cell‐inner plexiform layer; MS, multiple sclerosis; MS‐ON; multiple sclerosis‐associated optic neuritis; ON, optic neuritis; pRNFL, peripapillary retinal nerve fiber layer; SD, standard deviation.
1Without previous MS‐ON
*
All p‐values are two‐sided from two sample t‐test comparing the MS and reference groups. p‐values for the subgroup comparison MS‐ON versus non‐MS‐ON were also calculated and were all <0.0001.